Greg Mayes, J.D. is an accomplished life sciences leader with over 25 years in the pharmaceutical drug development space. He is currently the President and CEO of Reunion Neuroscience, where he's leading the Company’s advancement of next-generation psychedelic therapeutic solutions for neuropsychiatric indications such as postpartum depression and adjustment disorder. Prior to joining Reunion Neuroscience, Greg founded Engage Therapeutics and served as the Company’s President and CEO. He led Engage through successful Phase 2b efficacy studies of the first and only drug-device combination for rapid termination of an active epileptic seizure, which led to the Company’s acquisition by UCB. Following the sale of Engage, Greg was President and CEO of Antios Therapeutics, a venture backed company in the infectious disease space. He has also played integral roles in leading fund-raising, partnering, and acquisitions at Advaxis Immunotherapies as COO, and at ImClone Systems Corporation, as Vice President, General Counsel, and CCO.